Prosecution Insights
Last updated: November 16, 2026
Application No. 18/252,025

Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof

Non-Final OA §102§103§DOUBLEPATENT
Filed
Oct 09, 2023
Priority
Nov 06, 2020 — AU 2020904060 +1 more
Examiner
STOCKTON, LAURA LYNNE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Actinogen Medical Limited
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1030 granted / 1368 resolved
+15.3% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
1398
Total Applications
across all art units

Office Action

§102 §103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-5, 7, 9-11, 13, 17, 18, 23-25, 27, 31, 32, 36 and 37 are pending in the instant application. Election/Restrictions Applicant’s election without traverse of Group I, PNG media_image1.png 204 602 media_image1.png Greyscale , and the species of the compound of Formula 4a, PNG media_image2.png 110 170 media_image2.png Greyscale , in the reply filed on June 11, 2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Claims 10, 11, 13, 17, 18, 23-25, 27, 31, 32, 36 and 37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on June 11, 2026. It is suggested that in order to advance prosecution, the non-elected subject matter in which rejoinder is not applicable (i.e., the claims of non-elected Groups II-IV) be canceled if Applicant files a response to this Office Action. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The Examiner has considered the Information Disclosure Statement filed on May 8, 2023. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claim 1 is objected to because of the following informalities: in claim 1, under the definition of variable R1, an “and” should be added between “-COR3,” and “CO2R3,” (the 4th line from the end of the claim). Appropriate correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5, 7 and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-11 and 15-25 of copending Application No. 19/161,127 (reference application), US 2026/0242370. Although the claims at issue are not identical, they are not patentably distinct from each other because copending Application No. 19/161,127 claims a process for making an aza-bicyclic compound of Formula 1, PNG media_image3.png 94 110 media_image3.png Greyscale , comprising reacting a nortropinone compound of Formula 2, PNG media_image4.png 88 106 media_image4.png Greyscale , with a halogenated compound of Formula 3, PNG media_image5.png 54 78 media_image5.png Greyscale . The Specification on page 47 of copending Application No. 19/161,127 discloses a reaction which is embraced by its claims in Scheme 1, PNG media_image6.png 132 544 media_image6.png Greyscale The instant application and copending Application No. 19/161,127 share the same assignee. The instant application is not related to copending Application No. 19/161,127 and thus, no 35 USC 121 shield exists here. See MPEP 804.01. Therefore, the claims in copending Application No. 19/161,127 anticipate and/or render obvious the instant claimed invention. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Webster et al. {U.S. Patent 9,365,564}. Applicant claims a process for preparing an aza-bicyclic compound of Formula 4, PNG media_image7.png 96 136 media_image7.png Greyscale , comprising a Grignard reaction of a nortropinone compound of Formula 5, PNG media_image8.png 100 122 media_image8.png Greyscale , with a halogenated compound of Formula 6, PNG media_image9.png 56 92 media_image9.png Greyscale , wherein R1 can represent an unsubstituted or substituted monocyclic heterocyclyl, which monocyclic heterocyclyl can be aromatic (such as pyrazine and pyrimidine); R2 represents an amine protecting group (such as a benzyl or a tert-butyloxycarbonyl group); and X represents a halogen. Webster et al. disclose, for instance, Synthesis 15 (columns 84-85) and Synthesis 31 (column 96), PNG media_image10.png 222 272 media_image10.png Greyscale PNG media_image11.png 196 218 media_image11.png Greyscale PNG media_image12.png 536 470 media_image12.png Greyscale . Therefore, Webster et al. anticipate the instant claimed invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Webster et al. {U.S. Patent 9,365,564}, taken alone, and in further view of Delia {Journal of Heterocyclic Chemistry, 50(4), July 2013, pages 735-745}. Determination of the scope and content of the prior art (MPEP §2141.01) Applicant claims a process for preparing an aza-bicyclic compound of Formula 4, PNG media_image7.png 96 136 media_image7.png Greyscale , comprising a Grignard reaction of a nortropinone compound of Formula 5, PNG media_image8.png 100 122 media_image8.png Greyscale , with a halogenated compound of Formula 6, PNG media_image9.png 56 92 media_image9.png Greyscale , wherein R1 can represent an unsubstituted or substituted monocyclic heterocyclyl (such as pyrazine and pyrimidine); R2 represents an amine protecting group (such as a benzyl or a tert-butyloxycarbonyl group); and X represents a halogen. Webster et al. teach processes for producing aza-bicyclic compounds (such as PNG media_image13.png 208 204 media_image13.png Greyscale , PNG media_image14.png 292 274 media_image14.png Greyscale and PNG media_image15.png 242 280 media_image15.png Greyscale ) in which a nitrogen protected nortropinone compound (such as PNG media_image16.png 202 150 media_image16.png Greyscale and PNG media_image17.png 198 154 media_image17.png Greyscale ) is used as the starting material. Webster et al. disclose, for instance, Synthesis 15 (columns 84-85) and Synthesis 31 (column 96), PNG media_image10.png 222 272 media_image10.png Greyscale PNG media_image11.png 196 218 media_image11.png Greyscale PNG media_image12.png 536 470 media_image12.png Greyscale . Ascertainment of the difference between the prior art and the claimed invention (MPEP §2141.02) The difference, if any, between the processes of Webster et al. and the process instantly claimed, especially in instant claim 9, is that of analogous reactants/starting materials. Finding of prima facie obviousness--rational and motivation (MPEP §2142-2143) However, Synthesis 3 (column 74) in Webster et al. prepares the product of instant Formula 4a, PNG media_image18.png 110 170 media_image18.png Greyscale , stated in instant claim 9. Synthesis 15 (columns 84-85) and Synthesis 17 (column 85) in Webster et al. teach that iodine can be used as the halogen in the starting material of instant Formula 6 in instant claim 1. Further, Delia discloses Compound 37, PNG media_image19.png 134 94 media_image19.png Greyscale , in Scheme 11 on page 737, which is the compound of instant Formula 6a, PNG media_image20.png 96 98 media_image20.png Greyscale , in instant claim 9. Synthesis 3 (column 74) and Synthesis 31 (column 96) in Webster et al. teach the tropinone compound of instant Formula 5a, PNG media_image21.png 98 124 media_image21.png Greyscale , in instant claim 9 and that said tropinone compound can be used as a starting material in the process. The use of analogous reactants in a known process is prima facie obvious. In re Durden, 226 USPQ 359 (Fed. Cir. 1985). Once the general reaction has been shown to be old, the burden is on Applicants to present reasons or authority for believing that a group on the starting material would take part in or affect the basic reaction and thus alter the nature of the product or the operability of the process. In looking at the instant claimed process as a whole, as stated in In re Ochiai, 37 USPQ2d 1127 (Fed. Cir. 1995), the claimed process would have been suggested to one skilled in the art. Note to Applicant: Not every piece of prior art found in the database search or class/subclass search which would anticipate and/or render obvious the instant claimed invention under examination has been applied against the instant currently pending claims under examination. See MPEP 904.03. Reminder to Applicant As a reminder, Applicant should specifically point out the support in the original disclosure {i.e., page number(s) and line number(s)} for any new claims or amended claims and for any amendments made to the disclosure. Making generic statements such as “all amendments are fully supported in the originally filed disclosure or the originally filed claims” without specifying page numbers and originally filed claim numbers are insufficient. See MPEP §714.02 and MPEP §2163.06(I). Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Laura L. Stockton (571) 272-0710. The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor, James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620 Technology Center 1600 August 26, 2026 Book XXIX, page 55
Read full office action

Prosecution Timeline

Oct 09, 2023
Application Filed
Aug 28, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12789175
PORPHYRIN PHOTOSENSITIZER AND COBALOXIME COCATALYST AND METHODS OF USE THEREOF
4y 4m to grant Granted Nov 10, 2026
Patent 12790350
NEW THIAZOLOPYRIMIDINONE DERIVATIVES
3y 1m to grant Granted Nov 10, 2026
Patent 12773396
Prodrugs of Fumarates and Their Use in Treating Various Diseases
2y 3m to grant Granted Oct 27, 2026
Patent 12767656
TRICYCLIC COMPOUND AND USE THEREOF
3y 3m to grant Granted Oct 20, 2026
Patent 12747251
INHIBITOR OF BTK AND MUTANTS THEREOF
4y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+33.6%)
Low
PTA Risk
Based on 1368 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month